Novartis Ag

Jacky Vonderscher

Armin Meinzer

Barbara Haeberlin

Ulrich Posanski

Birgit Hauer

Gerd Fricker

Ching-Pong Mak

Richard Sedrani

Friedrich Richter

Sylvain Cottens

Frank Dieterle

Gerard Maurer

Daniel Wahl

Elias Perentes

Olivier Grenet

Frank Städtler

Daniel Robert Roth

André Cordier

Andreas Mahl

The present invention is directed, in part, to a method of measuring &#x3b2;--microglobulin to assess glomerular alteration or damage of the kidney.

Use of &#x3b2;-2-microglobulin to assess glomerular alterations and damage in the kidney

This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant. The active agent may be a cyclosporin or a macrolide. In another aspect, this invention provides a pharmaceutical composition for enteral or parenteral administration comprising a macrolide and an acid.

Pharmaceutical compositions

A pharmaceutical composition containing macrolide, e.g. a rapamycin compound in an emulsion preconcentrate or microemulsion preconcentrate for oral administration. The carrier medium for the rapamycin compound includes a hydrophilic phase, a lipophilic phase and a surfactant. The composition is stable and provides high absorption efficiency.

Galenical formulations

Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-, di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesterified corn oil is provided representing a mixed mono-, di- and tri-glyceride suitable for the novel formulation. Dosage forms include in particular oral dosage forms.

Pharmaceutical Composition

A pharmaceutical composition in the form of an emulsion preconcentrate for oral administration and containing a cyclosporin. The pharmaceutical composition has a carrier medium for the cyclosporin that contains a hydrophilic organic solvent; a mixed mono-, di-, and tri-glyceride or a transesterified and polyethoxylated vegetable oil; and a polyoxyethylene-sorbitan-fatty acid ester surfactant. The pharmaceutical composition provides high bioavailability and low inter- and intra-subject variability.

Pharmaceutical compositions containing cyclosporins

This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.

Enteric coated pharmaceutical compositions

Pharmaceutical compositions containing cyclosporin as the active agent

Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-,di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesterified corn oil is provided representing a mixed mono-, di- and tri-glyceride suitable for the novel formulation. Dosage forms include in particular oral dosage forms.

Pharmaceutical composition

Entric-coated pharmaceutical compositions

Enteric-coated pharmaceutical compositions of mycophenolate

Growing community of inventors

Riedisheim, France

Jacky Vonderscher